Exhibit 118 · Surveillance report
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Myocarditis reporting rates were 40.6 cases per million second doses of mRNA COVID-19 vaccines administered to males aged 12−29 years and 2.4 per million second doses administered to males aged ≥30 years
VAERS reports showed myocarditis within seven days of the second mRNA dose at about 40.6 cases per million doses in males aged 12–29, against 2.4 per million in males 30 and older.
- Source
- Centers for Disease Control and Prevention, MMWR 70(27):977–982
- Date
- 9 July 2021
- Quoted from
- MMWR 2021;70(27):977-982 (published 9 July 2021), Results, VAERS paragraph
- Grade
- Primary record
- Document
- https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit